PHAXIAM Therapeutics S.A. Market Cap ($1.01 Million)
Market Cap & Net Worth: PHAXIAM Therapeutics S.A. (PHXM)
PHAXIAM Therapeutics S.A. market cap. PHAXIAM Therapeutics S.A. (PA:PHXM) has a market capitalization of $1.01 Million (€863.96K) as of October 31, 2026. Listed on the PA stock exchange, this France-based company holds position #30677 globally and #573 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PHAXIAM Therapeutics S.A.'s stock price €0.10 by its total outstanding shares 10050400 (10.05 Million).
PHAXIAM Therapeutics S.A. Market Cap History (2015–2025)
PHAXIAM Therapeutics S.A. market cap history from 2015 to 2025. Data shows change from $2.78 Billion to $1.18 Million (-54.94% CAGR). Check PHAXIAM Therapeutics S.A. (PHXM) share price today for real-time trading data and today's change.
Index Memberships
PHAXIAM Therapeutics S.A. is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC Mid & Small
CACMS
|
$221.72 Billion | 0.00% | #109 of 119 |
|
CAC Small90
CACS
|
$35.70 Billion | 0.00% | #58 of 64 |
|
CAC All-Tradable
CACT
|
$2.79 Trillion | 0.00% | #169 of 179 |
|
CAC All-Tradable Net Total Return
CACTN
|
$2.79 Trillion | 0.00% | #169 of 179 |
|
CAC All Tradable Gross Total Return
CACTR
|
$2.79 Trillion | 0.00% | #169 of 179 |
|
CAC Health Care
FRHC
|
$262.86 Billion | 0.00% | #34 of 36 |
Weight: PHAXIAM Therapeutics S.A.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
PHAXIAM Therapeutics S.A. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PHAXIAM Therapeutics S.A.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see PHAXIAM Therapeutics S.A. (PHXM) cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
37.67x
PHAXIAM Therapeutics S.A.'s market cap is 37.67 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.78 Billion | $2.93 Million | -$15.01 Million | 949.91x | N/A |
| 2016 | $1.49 Billion | $4.14 Million | -$22.01 Million | 360.59x | N/A |
| 2017 | $2.01 Billion | $3.36 Million | -$33.53 Million | 597.23x | N/A |
| 2018 | $678.74 Million | $4.45 Million | -$38.22 Million | 152.63x | N/A |
| 2019 | $727.61 Million | $5.28 Million | -$62.66 Million | 137.73x | N/A |
| 2020 | $772.13 Million | $3.72 Million | -$73.30 Million | 207.67x | N/A |
| 2021 | $230.23 Million | $4.18 Million | -$53.80 Million | 55.08x | N/A |
| 2022 | $39.83 Million | $6.65 Million | -$228.00K | 5.99x | N/A |
| 2023 | $49.96 Million | $1.33 Million | -$23.49 Million | 37.67x | N/A |
Competitor Companies of PHXM by Market Capitalization
Companies near PHAXIAM Therapeutics S.A. in the global market cap rankings as of October 31, 2026. See PHAXIAM Therapeutics S.A. net asset quality index to understand what proportion of total assets are financed by equity.
Key companies related to PHAXIAM Therapeutics S.A. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of PHAXIAM Therapeutics S.A. (2015–2025)
Market capitalization of PHAXIAM Therapeutics S.A. from 2015 to today. Between 2015 and today, PHAXIAM Therapeutics S.A.'s market cap moved from $2.78 Billion to $ 1.18 Million, with a yearly change of -54.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €1.18 Million | -94.05% |
| 2024 | €19.86 Million | -60.25% |
| 2023 | €49.96 Million | +25.41% |
| 2022 | €39.83 Million | -82.70% |
| 2021 | €230.23 Million | -70.18% |
| 2020 | €772.13 Million | +6.12% |
| 2019 | €727.61 Million | +7.20% |
| 2018 | €678.74 Million | -66.22% |
| 2017 | €2.01 Billion | +34.64% |
| 2016 | €1.49 Billion | -46.37% |
| 2015 | €2.78 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of PHAXIAM Therapeutics S.A. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.01 Million USD |
| MoneyControl | $1.01 Million USD |
| MarketWatch | $1.01 Million USD |
| marketcap.company | $1.01 Million USD |
| Reuters | $1.01 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PHAXIAM Therapeutics S.A.
PHAXIAM Therapeutics S.A., a clinical-stage biopharmaceutical company, focuses on developing bacteriophage-based therapies for severe resistance infections in France. The company develops and commercializes red cell-based therapies for cancers and orphan diseases. It develops anti-infectious therapies based on the use of bacteriophages (phages) to treat infections caused by Escherichia coli (E.co… Read more